** Drug developer PaxMedica's shares rise 9.1% to 72 cents in extended trading
** PXMD says it has received Malawi health ministry's urgent request for emergency access to IV suramin
** Suramin is used to treat sleeping sickness
** Company recently announced it has completed execution of three pivotal registration/validation batches of PAX-101 (an IV form of suramin)
** Company will file marketing application for drug with U.S. FDA
** Up to last close, stock down 12.8% YTD
(Reporting by Christy Santhosh)
((Christy.Santhosh@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments